Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

This article has been Reviewed by the following groups

Read the full article

Abstract

SARS-CoV-2 variants with adaptive mutations have continued to emerge, causing fresh waves of infection even amongst vaccinated population. The development of broad-spectrum antivirals is thus urgently needed. We previously developed two hetero-bivalent nanobodies (Nbs), aRBD-2-5 and aRBD-2-7, with potent neutralization activity against the wild-type (WT) Wuhan isolated SARS-CoV-2, by fusing aRBD-2 with aRBD-5 and aRBD-7, respectively. Here, we resolved the crystal structures of these Nbs in complex with the receptor-binding domain (RBD) of the spike protein, and found that aRBD-2 contacts with highly-conserved RBD residues and retains binding to the RBD of the Alpha, Beta, Gamma, Delta, Delta plus, Kappa, Lambda, Omicron BA.1, and BA.2 variants. In contrast, aRBD-5 and aRBD-7 bind to less-conserved RBD epitopes non-overlapping with the epitope of aRBD-2, and do not show apparent binding to the RBD of some variants. However, when fused with aRBD-2, they effectively enhance the overall binding affinity. Consistently, aRBD-2-5-Fc and aRBD-2-7-Fc potently neutralized all of the tested authentic or pseudotyped viruses, including WT, Alpha, Beta, Gamma, Delta, and Omicron BA.1, BA.1.1 and BA.2. Furthermore, aRBD-2-5-Fc provided prophylactic protection against the WT and mouse-adapted SARS-CoV-2 in mice, and conferred protection against the Omicron BA.1 variant in hamsters prophylactically and therapeutically, indicating that aRBD-2-5-Fc could potentially benefit the prevention and treatment of COVID-19 caused by the emerging variants of concern. Our strategy provides new solutions in the development of broad-spectrum therapeutic antibodies for COVID-19.

Article activity feed

  1. SciScore for 10.1101/2022.03.08.483381: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variableaRBD-2-5-Fc prophylactic protection in mice: Female K-18 hACE2 transgenic mice (The Jackson Laboratory) were administered with one dose of aRBD-2-5-Fc (10 mg/kg, i.p.) 24 hr before infected with 2 ×104 PFU of original SARS-CoV-2 (i.n.), and female A/J mice (The Jackson Laboratory) were administered with one dose of aRBD-2-5-Fc (1 mg/kg and 0.1 mg/kg, i.p.) 24 hr before infected with 1 ×105 PFU of mouse-adapted SARS-CoV-2 (intratracheally), body weight and death of the mice were monitored daily for 7 days post infection.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    After four washes with PBST (PBS containing 0.1% tween-20), bound Nb-Fc were detected with a HRP-conjugated anti-IgG1 Fc antibody (Sino Biological).
    anti-IgG1
    suggested: None
    After 2days of infection, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-100, blocked with DMEM containing 10% fetal bovine serum, and stained with a rabbit monoclonal antibody against SARS-CoV-2 NP (GeneTex, GTX635679) and an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (Thermo Fisher Scientific)
    SARS-CoV-2 NP
    suggested: None
    GTX635679
    suggested: (GeneTex Cat# GTX635679, RRID:AB_2888553)
    anti-mouse
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    The recombinant vectors were transiently transfected into HEK293F cells with polyethyleneimine (Polyscience).
    HEK293F
    suggested: RRID:CVCL_6642)
    Briefly, Vero E6 cells were seeded overnight in 24-well culture plates at 1.5 ×105 per well.
    Vero E6
    suggested: None
    Experimental Models: Organisms/Strains
    SentencesResources
    aRBD-2-5-Fc prophylactic protection in mice: Female K-18 hACE2 transgenic mice (The Jackson Laboratory) were administered with one dose of aRBD-2-5-Fc (10 mg/kg, i.p.) 24 hr before infected with 2 ×104 PFU of original SARS-CoV-2 (i.n.), and female A/J mice (The Jackson Laboratory) were administered with one dose of aRBD-2-5-Fc (1 mg/kg and 0.1 mg/kg, i.p.) 24 hr before infected with 1 ×105 PFU of mouse-adapted SARS-CoV-2 (intratracheally), body weight and death of the mice were monitored daily for 7 days post infection.
    K-18 hACE2
    suggested: RRID:IMSR_GPT:T037657)
    A/J
    suggested: None
    Recombinant DNA
    SentencesResources
    Briefly, the coding sequences for SARS-CoV-2 RBD (amino acids 321 to 591) of original WT, Alpha (N501Y), Beta (K417N, E484K, N501Y), Gamma (K417T, E484K, N501Y), Delta (L452R, T478K), Delta plus (K417N, L452R, T478K), Kappa (L452R, E484Q) and Lambda (L452R, F490S) variant were cloned into pTT5 vector, which the C terminal contain a TEV cleavage site and a human IgG1 Fc.
    pTT5
    suggested: RRID:Addgene_52326)
    Software and Algorithms
    SentencesResources
    The data was analyzed using GraphPad Prism software.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    The total number of cells indicated by the nuclei staining and the infected cells indicated by the NP staining were quantified with the cellular analysis module of the Gen5 software (BioTek).
    Gen5
    suggested: (Gen5, RRID:SCR_017317)
    Subsequent models building and refinement were achieved using COOT and Phenix 62.
    COOT
    suggested: (Coot, RRID:SCR_014222)
    All structural figures were prepared by PyMOL.
    PyMOL
    suggested: (PyMOL, RRID:SCR_000305)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.